| Subject: | FDA Releases Information about Updated Prescribing Information for Gadolinium-Based Contrast Agents for Magnetic Resonance Imaging (MRI) |
| Category: | Food and Drug Administration (FDA)
|
| Published: | Tue, 2 Oct 2007 - 06:00 am |
| Audience: Radiologists, Nephrologists, Dermatologists, Other Healthcare ProfessionalsThe FDA has announced that manufacturers of Gadolinium-based Contrast Agents (GCBAs) for Magnetic Resonance Imaging (MRI) marketed as Magnevist, MultiHance, Omniscan, OptiMARK, ProHance have issued a Dear Healthcare Professional letter to inform healthcare professionals of the addition of a BOXED WARNING and revisions to the WARNING section of the prescribing information for Gadolinium-based contrast agents as... The full article is available to StayAlert subscribers. Click here for a free trial subscription. |
|
RESOURCES:
External Links:
|
|
StayAlert! provides immediate online healthcare compliance validation to our healthcare users. When faced with dramatic reductions in healthcare dollars, StayAlert! focuses on those processes that can save the most time and money. By automating labor-intensive activities, StayAlert! almost instantly produces a positive impact on the healthcare user's bottom line. The policies alone included with the StayAlert! notices can save you $65,000 or more in labor costs each year. Organizations will realize dramatic cost savings through elimination of labor intensity, increased productivity with the benefit of ensuring regulatory compliance. StayAlert! is the service-oriented supplier of health care's compliance needs. StayAlert! is the only comprehensive clinical and regulatory service providing organizations in the healthcare arena with practical applications to meet complex mandated federal requirements. |
|
